-
Mashup Score: 2ESOPEC Trial: FLOT Protocol Proves Superior to CROSS Regimen in Locally Advanced Esophageal Cancer - 5 hour(s) ago
The phase III ESOPEC trial, conducted in Germany, compared two regimens for locally advanced esophageal cancer and found an overall survival benefit with the perioperative FLOT protocol over the neoad…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment: Meeting Highlights - 6 hour(s) ago
The international meeting in Madrid of the newly formed Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE) was held in May 2024. This diverse forum in…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Failure to Diagnose and Statutes of Limitations: Lavern’s Law and Its Implications for Oncology - 8 hour(s) ago
When health-care providers, including oncologists, fail to promptly diagnose a medical condition or communicate their diagnosis to their patients, it can have devastating consequences for those patien…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Two Phase III Trials Report Benefit With Isatuximab-Based Regimens in Newly Diagnosed Multiple Myeloma - 10 hour(s) ago
In newly diagnosed, transplant-ineligible patients with multiple myeloma, treatment with the anti-CD38 monoclonal antibody isatuximab plus bortezomib, lenalidomide, and dexamethasone led to a 40% redu…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0RSClin Tool and Risk for Late Distant Recurrence in Breast Cancer - 11 hour(s) ago
A risk score integrating the 21-gene recurrence score with clinicopathologic factors—the RSClin tool—performed well in predicting risk of late distant recurrence in patients with breast cancer.
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
In a Chinese phase II study (NEOCAP), neoadjuvant camrelizumab plus apatinib produced promising complete response rates in patients with locally advanced microsatellite instability–high or mismatch re…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Multiple Myeloma: Using Absolute Lymphocyte Count to Predict Outcomes After CAR T-Cell Therapy - 1 day(s) ago
A simple blood test that measures lymphocyte counts may predict whether patients with relapsed multiple myeloma are going to respond well to CAR T-cell immunotherapy, according to a recent report.
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL - 1 day(s) ago
Two hallmark toxicities of CAR T-cell therapy may be rare after 2 weeks following infusion in patients with diffuse large B-cell lymphoma, supporting a shorter, more flexible toxicity monitoring perio…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Investigators have found that eliminating racial disparities in colorectal cancer testing may reduce the rate of colorectal cancer incidence and mortality among Black patients in the United States.
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
A phase II study found that celiac plexus radiosurgery showed promise in the alleviation of retroperitoneal pain syndrome in patients with pancreatic cancer or other tumors involving the celiac axis.
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
ESOPEC Trial: FLOT Protocol Proves Superior to CROSS Regimen in Locally Advanced Esophageal Cancer https://t.co/lpa5EmwGQs #esocsm #esophagealcancer #oncology #ASCO24